HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

European Society of Cardiology Congress

Billed as the largest cardiology conference of the year, coverage of the European Society of Cardiology Congress will consist of articles, Q&As, exclusive video interviews, and podcasts with leading experts in their respective fields.

PANTHER: P2Y12 Monotherapy Bests Aspirin for Secondary Prevention in Coronary Artery Disease

August 29, 2022

The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.

Dapagliflozin Proves HFpEF Benefit in DELIVER Trial

August 27, 2022

Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.

TIME Study: No Added Benefit from Nighttime Dosing of Blood Pressure Medications

August 26, 2022

Although the Hygia study suggested nighttime dosing could increase the benefit of risk reduction obtained from antihypertensive medications, the TIME study found no significant improvement in risk reduction afforded by nighttime dosing as compared to morning dosing of medication.

Modeling Study Sheds Light on Benefits on Lifelong Statin Therapy

August 25, 2022

A modeling study presented at ESC 2022 provides insight into the differences in potential benefits of statin therapy based on lifelong use, delayed initiation, and early discontinuation among patients across the spectrum of cardiovascular risk.